Targeting glucose metabolism for cancer therapy

Journal of Experimental Medicine

Volumn 209, Issue 2, 2012, Pages 211-215

  Hamanaka, Robert B ^a   Chandel, Navdeep S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 PHOSPHOFRUCTOKINASE; ADENOSINE TRIPHOSPHATE; BETA CATENIN; FLUORODEOXYGLUCOSE F 18; FRUCTOSE; FRUCTOSE 6 PHOSPHATE; GALACTOSE; GLUCOSE 6 PHOSPHATE; GLUCOSE TRANSPORTER 1; GLYCERALDEHYDE 3 PHOSPHATE; HEXOKINASE; HEXOKINASE 2; HYDROGEN PEROXIDE; HYPOXIA INDUCIBLE FACTOR 1; LACTATE DEHYDROGENASE; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHOGLYCERATE DEHYDROGENASE; PYRUVATE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIBOSE 5 PHOSPHATE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER THERAPY; CELL DEATH; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; ELECTRON TRANSPORT; EPIGENETICS; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE TRANSPORT; GLYCOLYSIS; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PENTOSE PHOSPHATE CYCLE; PKA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH;

BIOSYNTHETIC PATHWAYS; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DRUG DELIVERY SYSTEMS; GLUCOSE; GLYCOLYSIS; HUMANS; NEOPLASMS;

EID: 84856860890     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20120162     Document Type: Short Survey

References (33)

1. Anastasiou, D., G. Poulogiannis, J.M. Asara, M.B. Boxer, J.K. Jiang, M. Shen, G. Bellinger, A.T. Sasaki, J.W. Locasale, D.S. Auld, et al. 2011. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science. 334:1278-1283. http://dx.doi.org/10.1126/science.1211485
2. Bluemlein, K., N.M. Grüning, R.G. Feichtinger, H. Lehrach, B. Kofler, and M. Ralser. 2011. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget. 2:393-400.
3. Chan, D.A., P.D. Sutphin, P. Nguyen, S. Turcotte, E.W. Lai, A. Banh, G.E. Reynolds, J.T. Chi, J. Wu, D.E. Solow-Cordero, et al. 2011. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med. 3:ra70.
4. Christofk, H.R., M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten, R. Wei, M.D. Fleming, S.L. Schreiber, and L.C. Cantley. 2008a. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 452:230-233. http://dx.doi.org/10.1038/nature06734
5. Christofk, H.R., M.G. Vander Heiden, N. Wu, J.M. Asara, and L.C. Cantley. 2008b. Pyruvate kinase M2 is a phosphotyrosinebinding protein. Nature. 452:181-186. http://dx.doi.org/10.1038/nature06667
6. Colombo, S.L., M. Palacios-Callender, N. Frakich, J. De Leon, C.A. Schmitt, L. Boorn, N. Davis, and S. Moncada. 2010. Anaphase-promoting complex/cyclosome-Cdh1 coordinates glycolysis and glutaminolysis with transition to S phase in human T lymphocytes. Proc. Natl. Acad. Sci. USA. 107:18868-18873. http://dx.doi.org/10.1073/pnas.1012362107
7. Frezza, C., and E. Gottlieb. 2009. Mitochondria in cancer: not just innocent bystanders. Semin. Cancer Biol. 19:4-11. http://dx.doi.org/10.1016/j.semcancer.2008.11.008
8. Gambhir, S.S. 2002. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer. 2:683-693. http://dx.doi.org/10.1038/nrc882
9. Goldberg, M.S., and P.A. Sharp. 2012. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J. Exp. Med. 209:217-224. doi: 10.1084/jem.20111487.
10. Hitosugi, T., S. Kang, M.G. Vander Heiden, T.W. Chung, S. Elf, K. Lythgoe, S. Dong, S. Lonial, X. Wang, G.Z. Chen, et al. 2009. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2:ra73. http://dx.doi.org/10.1126/scisignal.2000431
11. Jae, H.J., J.W. Chung, H.S. Park, M.J. Lee, K.C. Lee, H.C. Kim, J.H. Yoon, H. Chung, and J.H. Park. 2009. The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model. Korean J. Radiol. 10:596-603. http://dx.doi.org/10.3348/kjr.2009.10.6.596
12. Le, A., C.R. Cooper, A.M. Gouw, R. Dinavahi, A. Maitra, L.M. Deck, R.E. Royer, D.L. Vander Jagt, G.L. Semenza, and C.V. Dang. 2010. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. USA. 107:2037-2042. http://dx.doi.org/10.1073/pnas.0914433107
13. Lee, J., H.K. Kim, Y.M. Han, and J. Kim. 2008. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int. J. Biochem. Cell Biol. 40:1043-1054. http://dx.doi.org/10.1016/j.biocel.2007.11.009
14. Locasale, J.W., and L.C. Cantley. 2011. Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 14:443-451. http://dx.doi.org/10.1016/j.cmet.2011.07.014
15. Locasale, J.W., A.R. Grassian, T. Melman, C.A. Lyssiotis, K.R. Mattaini, A.J. Bass, G. Heffron, C.M. Metallo, T. Muranen, H. Sharfi, et al. 2011. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43:869-874. http://dx.doi.org/10.1038/ng.890
16. Lunt, S.Y., and M.G. Vander Heiden. 2011. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27:441-464. http://dx.doi.org/10.1146/annurev-cellbio-092910-154237
17. Luo, W., H. Hu, R. Chang, J. Zhong, M. Knabel, R. O'Meally, R.N. Cole, A. Pandey, and G.L. Semenza. 2011. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxiainducible factor 1. Cell. 145:732-744. http://dx.doi.org/10.1016/j.cell.2011.03.054
18. Lv, L., D. Li, D. Zhao, R. Lin, Y. Chu, H. Zhang, Z. Zha, Y. Liu, Z. Li, Y. Xu, et al. 2011. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell. 42:719- 730. http://dx.doi.org/10.1016/j.molcel. 2011.04.025
19. Nieman, K.M., H.A. Kenny, C.V. Penicka, A. Ladanyi, R. Buell-Gutbrod, M.R. Zillhardt, I.L. Romero, M.S. Carey, G.B. Mills, G.S. Hotamisligil, et al. 2011. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17:1498-1503. http://dx.doi.org/10.1038/nm.2492
20. Pfeiffer, T., S. Schuster, and S. Bonhoeffer. 2001. Cooperation and competition in the evolution of ATP-producing pathways. Science. 292:504-507. http://dx.doi.org/10.1126/science.1058079
21. Possemato, R., K.M. Marks, Y.D. Shaul, M.E. Pacold, D. Kim, K. Birsoy, S. Sethumadhavan, H.K. Woo, H.G. Jang, A.K. Jha, et al. 2011. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 476:346-350. http://dx.doi.org/10.1038/nature10350
22. Reitzer, L.J., B.M. Wice, and D. Kennell. 1979. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 254:2669-2676.
23. Robey, R.B., and N. Hay. 2006. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene. 25:4683-4696. http://dx.doi.org/
24. Shim, H., C. Dolde, B.C. Lewis, C.S. Wu, G. Dang, R.A. Jungmann, R. Dalla-Favera, and C.V. Dang. 1997. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA. 94:6658-6663. http://dx.doi.org/10.1073/pnas.94.13.6658
25. Spoden, G.A., U. Rostek, S. Lechner, M. Mitterberger, S. Mazurek, and W. Zwerschke. 2009. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp. Cell Res. 315:2765-2774. http://dx.doi.org/10.1016/j.yexcr.2009.06.024
26. Vander Heiden, M.G., L.C. Cantley, and C.B. Thompson. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 324: 1029-1033. http://dx.doi.org/10.1126/science.1160809
27. Vander Heiden, M.G., J.W. Locasale, K.D. Swanson, H. Sharfi, G.J. Heffron, D. Amador-Noguez, H.R. Christofk, G. Wagner, J.D. Rabinowitz, J.M. Asara, and L.C. Cantley. 2010. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science. 329:1492-1499. http://dx.doi.org/10.1126/science.1188015
28. Vora, S., J.P. Halper, and D.M. Knowles. 1985. Alterations in the activity and isozymic profile of human phosphofructokinase during malignant transformation in vivo and in vitro: transformation-and progression-linked discriminants of malignancy. Cancer Res. 45:2993-3001.
29. Warburg, O, K. Posener, and E. Negelein. 1924. Über den Stoffwechsel der Carcinomzelle. Biochem. Zeitschr. 152:309-344.
30. Warburg, O. 1956. On the origin of cancer cells. Science. 123:309-314. http://dx.doi.org/10.1126/science.123.3191.309
31. Yang, W., Y. Xia, H. Ji, Y. Zheng, J. Liang, W. Huang, X. Gao, K. Aldape, and Z. Lu. 2011. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature. 480:118-122. http://dx.doi.org/10.1038/nature10598
32. Younes, M., L.V. Lechago, J.R. Somoano, M. Mosharaf, and J. Lechago. 1996. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 56:1164-1167.
33. Zu, X.L., and M. Guppy. 2004. Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys. Res. Commun. 313:459-465. http://dx.doi.org/10.1016/j.bbrc.2003.11.136